NCT03508700View on ClinicalTrials.gov

A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 19, 2018

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions

PTSD

Interventions

DRUG

TNX-102 SL 5.6 mg

cyclobenzaprine HCl sublingual tablets

Trial Locations (16)

10128

New York, New York

11516

Cedarhurst, Cedarhurst

30341

Atlanta, Atlanta

33609

Tampa, Tampa

44718

Canton, Canton

45219

Cincinnati, Cincinnati

72211

Little Rock, Little Rock

73103

Oklahoma City, Oklahoma City

80910

Colorado Springs, Colorado Springs

89102

Las Vegas, Las Vegas

90210

Beverly Hills, Beverly Hills

92056

Oceanside, Oceanside

92591

Temecula, Temecula

92868

Orange, Orange

06360

Norwich, Norwich

02740

New Bedford, New Bedford

All Listed Sponsors

lead

Tonix Pharmaceuticals, Inc.

INDUSTRY

NCT03508700 - A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD | Biotech Hunter | Biotech Hunter